Related Experiment Video
Updated: Mar 28, 2026
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Recent advances in the field of anti-cancer immunotherapy
Henrique Neves1, Hang Fai Kwok1
1Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau.
Background:
The main goal of anti-cancer therapy is to specifically inhibit the malignant activity of cancer cells, while leaving healthy cells unaffected. As such, for every proposed therapy, it is important to keep in mind the therapeutic index - the ratio of the toxic dose over the therapeutic dose. The use of immunotherapy has allowed a means to both specifically block protein-protein interaction and deliver cytotoxic events to a tumor-specific antigen.
Review Scope:
It is the objective of this review to give an overview on current immunotherapy treatment for cancers using monoclonal antibodies. We demonstrate three exciting targets for immunotherapy, TNF-α Converting Enzyme (TACE), Cathepsin S and Urokinase Plasmogen Activator and go over the advances made with one of the most used monoclonal antibodies in cancer therapy, Rituximab; as well as Herceptin, which is used for breast cancer therapy. Furthermore, we touch on other venues of immunotherapy, such as adaptive cell transfer, the use of nucleic acids and the use of dendritic cells. Finally, we summarize some ongoing studies that spell tentative advancements for anti-cancer immunotherapy.
General Significance:
Immunotherapy is at the forefront of anti-cancer therapies, allying both a high degree of specificity to general high effectiveness and fewer side-effects.
Insights
Cancer immunotherapy harnesses monoclonal antibodies to target tumor-specific antigens, offering high specificity and effectiveness with fewer side effects. This review explores key targets and advancements in immunotherapy treatments.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Anti-cancer therapy aims for specific inhibition of malignant cells while sparing healthy ones.
- Therapeutic index is crucial for evaluating anti-cancer drug safety and efficacy.
- Immunotherapy offers targeted protein-protein interaction blockade and cytotoxic delivery to tumor antigens.
Purpose of the Study:
- To review current cancer immunotherapy treatments utilizing monoclonal antibodies.
- To highlight promising targets such as TNF-α Converting Enzyme (TACE), Cathepsin S, and Urokinase Plasminogen Activator.
- To discuss advancements in established therapies like Rituximab and Herceptin.
Main Methods:
- Review of current literature on cancer immunotherapy.
- Analysis of monoclonal antibody applications in oncology.
- Exploration of emerging immunotherapy modalities.
Main Results:
- Monoclonal antibodies provide targeted approaches for cancer treatment.
- Specific targets like TACE, Cathepsin S, and UPA show potential for immunotherapy.
- Established antibodies (Rituximab, Herceptin) demonstrate efficacy in various cancers.
Conclusions:
- Immunotherapy represents a leading strategy in anti-cancer treatment.
- High specificity and effectiveness, coupled with reduced side effects, characterize modern immunotherapy.
- Ongoing research suggests continued advancements in the field of anti-cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies